439 related articles for article (PubMed ID: 32098830)
1. Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.
Hotta K; Fujimoto N
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32098830
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab for the treatment of unresectable pleural mesothelioma.
Hotta K; Fujimoto N; Kozuki T; Aoe K; Kiura K
Expert Opin Biol Ther; 2020 Feb; 20(2):109-114. PubMed ID: 31825692
[No Abstract] [Full Text] [Related]
3. Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma.
Metro G; Signorelli D; Pizzutilo EG; Giannetta L; Cerea G; Garaffa M; Friedlaender A; Addeo A; Mandarano M; Bellezza G; Roila F
Hum Vaccin Immunother; 2021 Sep; 17(9):2972-2980. PubMed ID: 34003722
[TBL] [Abstract][Full Text] [Related]
4. A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.
Shah R; Klotz LV; Chung I; Feißt M; Schneider MA; Riedel J; Bischoff H; Eichhorn ME; Thomas M
Clin Lung Cancer; 2021 Mar; 22(2):142-146. PubMed ID: 33158765
[TBL] [Abstract][Full Text] [Related]
5. [Research Progress of Immune Checkpoint Inhibitors
in Malignant Pleural Mesothelioma].
Huang Y; Meng Q
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):441-446. PubMed ID: 34157803
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
Cui W; Popat S
Drugs; 2021 Jun; 81(9):971-984. PubMed ID: 34106454
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress.
Perrino M; De Vincenzo F; Cordua N; Borea F; Aliprandi M; Santoro A; Zucali PA
Front Immunol; 2023; 14():1121557. PubMed ID: 36776840
[TBL] [Abstract][Full Text] [Related]
8. [Clinical analysis of combined immunotherapy in patients with malignant pleural mesothelioma].
Zhao C; Fei KL; Wan R; Song LP; Xiang PC; Duan JC
Zhonghua Zhong Liu Za Zhi; 2023 May; 45(5):445-451. PubMed ID: 37188631
[No Abstract] [Full Text] [Related]
9. Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges.
Parikh K; Hendriks LEL; Bironzo P; Remon J
Cancer Treat Rev; 2021 Sep; 99():102250. PubMed ID: 34174669
[TBL] [Abstract][Full Text] [Related]
10. CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.
Uprety D
Clin Lung Cancer; 2021 Mar; 22(2):71-73. PubMed ID: 33358660
[No Abstract] [Full Text] [Related]
11. Emerging biological therapies for the treatment of malignant pleural mesothelioma.
Davis AP; Kao SC; Clarke SJ; Boyer M; Pavlakis N
Expert Opin Emerg Drugs; 2021 Jun; 26(2):179-192. PubMed ID: 33945357
[No Abstract] [Full Text] [Related]
12. [Not Available].
Mignard X; Chaabane N; Fallet V; Wislez M
Bull Cancer; 2018 Dec; 105 Suppl 1():S16-S23. PubMed ID: 30595194
[TBL] [Abstract][Full Text] [Related]
13. Malignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors.
Martella S; Aiello MM; Bertaglia V; Cau R; Denaro N; Cadoni A; Novello S; Scartozzi M; Novello G; Soto Parra HJ; Saba L; Solinas C; Porcu M
Target Oncol; 2024 Jan; 19(1):13-28. PubMed ID: 38063957
[TBL] [Abstract][Full Text] [Related]
14. [Progress in treatment for malignant pleural mesothelioma].
Wang YY; He YL; Chi YJ; Zhai XY; An TT; Li JJ; Zhuo ML; Zhao J; Wang ZP
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Jan; 45(1):111-115. PubMed ID: 35000316
[TBL] [Abstract][Full Text] [Related]
15. [Anti-tumor immunotherapy in malignant pleural mesothelioma].
Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X
Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822
[TBL] [Abstract][Full Text] [Related]
16. Nose in malignant mesothelioma-Prediction of response to immune checkpoint inhibitor treatment.
Disselhorst MJ; de Vries R; Quispel-Janssen J; Wolf-Lansdorf M; Sterk PJ; Baas P
Eur J Cancer; 2021 Jul; 152():60-67. PubMed ID: 34087572
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.
Remon J; Passiglia F; Ahn MJ; Barlesi F; Forde PM; Garon EB; Gettinger S; Goldberg SB; Herbst RS; Horn L; Kubota K; Lu S; Mezquita L; Paz-Ares L; Popat S; Schalper KA; Skoulidis F; Reck M; Adjei AA; Scagliotti GV
J Thorac Oncol; 2020 Jun; 15(6):914-947. PubMed ID: 32179179
[TBL] [Abstract][Full Text] [Related]
18. A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
Fujimoto N; Aoe K; Kozuki T; Oze I; Kato K; Kishimoto T; Hotta K
Clin Lung Cancer; 2018 Sep; 19(5):e705-e707. PubMed ID: 29853412
[TBL] [Abstract][Full Text] [Related]
19. Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients.
Cedrés S; Ponce-Aix S; Iranzo P; Callejo A; Pardo N; Navarro A; Martinez-Marti A; Gómez-Abecia S; Zucchiatti AC; Sansano I; Enguita AB; Miquel JM; Viaplana C; Dienstmann R; Paz-Ares L; Felip E
Clin Transl Oncol; 2020 Aug; 22(8):1390-1398. PubMed ID: 31916017
[TBL] [Abstract][Full Text] [Related]
20. [Advances in Immunotherapy for Malignant Pleural Mesothelioma].
Chi Y; Liu Y; Zhao J
Zhongguo Fei Ai Za Zhi; 2022 Apr; 25(4):259-265. PubMed ID: 35477190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]